Methods for tumor treatment using dendrimer conjugates
First Claim
Patent Images
1. A method of treating a tumor in the lymphatic system, comprising:
- administering to a subject who has been identified as having a tumor a dendrimer conjugate that selectively concentrates in the lymphatic system of the subject, wherein the dendrimer conjugate comprises a generation 5 DAB or generation 3-10 PAMAM dendrimer conjugated to an amount of an anti-tumor agent effective to treat the identified tumor, but the dendrimer conjugate does not include a tumor specific targeting agent; and
treating the tumor with the anti-tumor agent.
1 Assignment
0 Petitions
Accused Products
Abstract
Methods are disclosed for treating a tumor. A dendrimer conjugate is administered to a subject having a tumor. The dendrimer of the dendrimer conjugate is a generation 5 DAB, generation 2 polylysine, or generation 6-8 PAMAM dendrimer. The dendrimer conjugate comprises an effective amount of an anti-tumor agent. The anti-tumor agent is selectively concentrated in the lymphatic system to treat metastatic disease. In certain examples, the anti-tumor agent is an activatable anti-tumor agent and is activated once the anti-tumor agent is selectively concentrated in the lymphatic system.
-
Citations
21 Claims
-
1. A method of treating a tumor in the lymphatic system, comprising:
-
administering to a subject who has been identified as having a tumor a dendrimer conjugate that selectively concentrates in the lymphatic system of the subject, wherein the dendrimer conjugate comprises a generation 5 DAB or generation 3-10 PAMAM dendrimer conjugated to an amount of an anti-tumor agent effective to treat the identified tumor, but the dendrimer conjugate does not include a tumor specific targeting agent; and
treating the tumor with the anti-tumor agent. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)
-
-
19. A method of inhibiting metastatic disease in a subject, comprising:
-
identifying a subject as having a tumor that spreads through the lymphatic system;
administering a dendrimer conjugate in the lymphatic system of the subject who has been identified as having a tumor, wherein the dendrimer conjugate comprises a generation 5 DAB or generation 3-10 PAMAM dendrimer and is capable of selectively concentrating in lymphatic structures and is conjugated to an amount of a gadolinium imaging agent that can be activated by a neutron beam to treat the identified tumor, wherein the dendrimer conjugate does not include a tumor specific targeting agent;
imaging the lymphatic system to detect the gadolinium imaging agent in the lymphatic system; and
selectively activating the gadolinium imaging agent by directing a neutron beam at a portion of the imaged lymphatic system, thereby treating metastatic disease that may be in the lymphatic system.
-
-
20. A method of inhibiting metastatic disease in a subject, comprising:
-
selecting a dendrimer conjugate having a diameter of about 4 nanometers to about 15 nanometers for administration to a subject who has been identified as having a tumor;
administering the dendrimer conjugate in the lymphatic system of the subject, wherein the dendrimer conjugate comprises a generation 5 DAB or generation 3-10 PAMAM dendrimer and is capable of selectively concentrating in lymphatic structures and is conjugated to an amount of a gadolinium imaging agent that can be activated by a neutron beam to treat the identified tumor;
imaging the lymphatic system to detect the gadolinium imaging agent in the lymphatic system; and
selectively activating the gadolinium imaging agent by directing a neutron beam at a portion of the imaged lymphatic system, thereby treating metastatic disease that may be in the lymphatic system. - View Dependent Claims (21)
-
Specification